Adc Therapeutics SA
Adc Therapeutics SA (ADCT) Historical Volatility
ADCT's 30 day historical volatility is 119.13%, in the 88th percentile of readings over the past year. This is a high percentile, meaning Adc Therapeutics SA shares have swung far more than usual. ADCT's 30 day implied volatility sits at 0.01%, with an IV Rank of 5.56%, leaving IV 119.12 points below historical volatility. This means options are pricing in less movement than the stock has actually delivered, as of Nov 16, 2026.
Read more
Tracking ADCT historical volatility helps you see how much Adc Therapeutics SA's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ADCT's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ADCT 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ADCT's 30 day historical volatility, or ADCT HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ADCT's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 16, 2026
As of Nov 16, 2026
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →